The identification and pharmacokinetic studies of metabolites of salvianolic acid B after intravenous administration in rats

Chinese Journal of Natural Medicines

Volumn 11, Issue 5, 2013, Pages 560-565

  Qi, Qu ^a   Hao, Kun ^a   Li, Fei Yan ^a   Cao, Li Juan ^a   Wang, Guang Ji ^a   Hao, Hai Ping ^a  

^a China Pharmaceutical University   (China)

Author keywords

Identification; Metabolites; Pharmacokinetics; Salvianolic acid B

Indexed keywords

ACETONITRILE; CHLORAMPHENICOL; DRUG METABOLITE; LITHOSPERMIC ACID; METHANOL; SALVIANOLIC ACID B;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DECARBOXYLATION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; METHYLATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY;

IDENTIFICATION; METABOLITES; PHARMACOKINETICS; SALVIANOLIC ACID B;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BENZOFURANS; BILE; MALE; MOLECULAR STRUCTURE; PLASMA; RATS; RATS, SPRAGUE-DAWLEY; URINE;

EID: 84890808756     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.1016/S1875-5364(13)60101-6     Document Type: Article

References (11)

1. Du GH, Qiu Y, Zhang JT Salvianolic acid B protects the memory functions against transient cerebral ischemia in mice [J]. J Asian Nat Prod Res 2000, 2(2):145-152.
2. Ho JHC, Hong CY Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection [J]. J Biomed Sci 2011, 18(1):30-34.
3. Chen YL, Hu CS, Lin FY, et al. Salvianolic acid B attenuates cyclooxygenase-2 expression in vitro in LPS-treated human aortic smooth muscle cells and in vivo in the apolipoprotein-E-deficient mouse aorta [J]. J Cell Biochem 2006, 98(3):618-631.
4. Han JY, Fan JY, Horie Y, et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion [J]. Pharmacol Ther 2008, 117(2):280-295.
5. Li M, Zhao C, Wong RN, et al. Inhibition of shear-induced platelet aggregation in rat by tetramethylpyrazine and salvianolic acid B [J]. Clin Hemorheol Microcirc 2004, 31(2):97-103.
6. Shi CS, Huang HC, Wu HL, et al. Salvianolic acid B modulates hemostasis properties of human umbilical vein endothelial cells [J]. Thromb Res 2007, 119(6):769-775.
7. Zhang Y, Akao T, Nakamura N, et al. Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza, in rat [J]. Planta Med 2004, 70(2):138-142.
8. Wu YT, Chen YF, Hsieh YJ, et al. Bioavailability of salvianolic acid B in conscious and freely moving rats [J]. Int J Pharm 2006, 326(1):25-31.
9. Li X, Yu C, Lu Y, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of depside salts from Salvia miltiorrhiza in rats [J]. Drug Metab Dispos 2007, 35(2):234-239.
10. Zhang Y, Akao T, Nakamura N, et al. Magnesium lithospermate B is excreted rapidly into rat bile mostly as methylated metabolites, which are potent antioxidants [J]. Drug Metab Dispos 2004, 32(7):752-757.
11. Xu M, Guo H, Han J, et al. Structural characterization of metabolites of salvianolic acid B from Salvia miltiorrhiza in normal and antibiotic-treated rats by liquid chromatography-mass spectrometry [J]. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 858(1-2):184-198.